Cardiac ablation stands as a pivotal medical intervention devised to address specific cardiac conditions, notably those entailing irregular heart rhythms or arrhythmias. Throughout this procedure, a catheter intricately navigates blood vessels to reach the heart, delivering energy, either through heat or cold, to targeted areas responsible for aberrant heart rhythms. The application of this energy generates minute scars, disrupting the abnormal electrical signals that underlie the arrhythmia. When conventional medications prove insufficient in managing irregular heartbeats, cardiac ablation emerges as a recommended and minimally invasive alternative. Its effectiveness is particularly notable in conditions like atrial fibrillation. As technology progresses, cardiac ablation continues to undergo advancements, positioning itself as a promising option for restoring normal heart rhythm and enhancing overall cardiac well-being.
Title : Personalized and precision medicine (PPM) as a unique healthcare model through biodesign-driven translational applications and cardiology-related healthcare marketing to secure the human healthcare and biosafety
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Beyond weight loss and diabetes control GLP 1 agonists paradigm shift in Cardiovascular care .
Syed Raza, Awali Hospital, Bahrain
Title : Vericiguat Inhibits the Progress of Cardiac Hypertrophy and Prevents Hypertrophy Induced Heart Failure by Multiple Mechanisms
Guo Wei He, TEDA International Cardiovascular Hospital, Tianjin University, China
Title : Coronary revascularization in patients with diabetes: Prospects for stenting in patients with type 1 diabetes and coronary artery disease
Mekhman N Mamedov, National Research Center for Therapy and Preventive Medicine, Russian Federation
Title : STEMI versus acute occlusive myocardial infarction: Which term should we use?
Yochai Birnbaum, Baylor College of Medicine, United States
Title : Chronic angina and the health economics of cardiovascular risk reduction in macro- and microvascular coronary disease
Uwe Peter Tigor, Auxilius Pharma, United States